Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates - Wikidata - awgldk - TriplyDB

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

http://www.wikidata.org/entity/Q29620051

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu B7-H5 costimulates human T cells via CD28H A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Safety, activity, and immune correlates of anti-PD-1 antibody in cancer Role of PD-1 in HIV pathogenesis and as target for therapy Immunobiology and immunotherapy in genitourinary malignancies Contemporary Treatment of Metastatic Renal Cell Carcinoma New targeted treatments for non-small-cell lung cancer - role of nivolumab PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Emerging molecular classifications and therapeutic implications for gastric cancer Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints Lymphocyte-activation gene-3, an important immune checkpoint in cancer Role of the tumor microenvironment in mature B-cell lymphoid malignancies Immunotherapy for cancer in the central nervous system: Current and future directions Clinical utility of nivolumab in the treatment of advanced melanoma Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Genetics and biology of pancreatic ductal adenocarcinoma The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response Advances in immunotherapy for melanoma PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment Novel technologies and emerging biomarkers for personalized cancer immunotherapy Viro-immune therapy: A new strategy for treatment of pancreatic cancer Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect Immune checkpoint inhibitors: therapeutic advances in melanoma Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma Promises and paradoxes of regulatory T cells in inflammatory bowel disease Molecular profiling in the treatment of colorectal cancer: focus on regorafenib Predictive factors for immunotherapy in melanoma Advances in immunotherapy for treatment of lung cancer Relevance of tumor-infiltrating lymphocytes in breast cancer Antagonists of PD-1 and PD-L1 in Cancer Treatment The progress of immunotherapy for glioblastoma The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients Nivolumab in the treatment of malignant melanoma: review of the literature Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics

P2860

Q21131200-A8FB79EA-00D3-48DC-BD53-A3F0D8FA32F7 Q24295841-3CC29CBE-F066-459E-95D1-CEEFF0B31F14 Q24606852-0AC7E35A-E546-4A5F-BC90-210AC650E1E4 Q24633070-5D78B785-F70A-4EC4-BE68-04A006C0470A Q24634293-5CF5DB0A-D657-4E1C-B67C-4C2B3EFA2908 Q26738668-B2BE97E2-BDCE-41DF-A63B-654ACE800DB0 Q26740594-4AB1DD57-8426-4B06-A012-63B7F2613EE7 Q26740988-376A8319-6424-49CF-A41E-BA7BDE19F138 Q26741101-4AA354D1-0CD7-432B-BAAC-3F5A83B25242 Q26744076-73950C12-414A-427F-9637-AC6D3DF74787 Q26745525-44BA7D91-26CD-4685-9FE2-0569A77CF443 Q26745590-661EFD15-1B78-4497-B45C-C1169790DF6A Q26745842-2794B1FE-34B6-4F02-9A18-C1C7DD4A0FEE Q26746209-0C310A36-A67E-4D00-9C54-02604CB6603E Q26748775-6861F405-D284-43D3-885F-666A1302D684 Q26750765-5030940A-7A52-49CE-948A-231D84E18E11 Q26751268-3CEF4344-D37F-40CA-8F20-F8D5021EF231 Q26751344-6FCB7C9B-2C90-4309-B18F-C0E435927514 Q26753082-FBFB2A63-2A5E-4141-B869-0C8D118D9486 Q26765438-B9E38970-DADF-4A67-BA95-E05302743E14 Q26766066-82BEBFD3-DD3D-4322-BFF0-F6BD94DC2047 Q26768558-726F5571-CD3B-4C1F-91B1-4CA06A68CF73 Q26768641-2B04612E-4668-4369-95C7-3305AEAB400C Q26769713-67EDBFB1-1CDD-4119-8D95-9F6C4EAE275D Q26769963-D83CF563-A2B3-4209-9A9A-3B19D4FB1E8D Q26770780-75387215-AF4F-4AAB-ACA1-EFA2233F77C8 Q26774641-F5078E55-9900-4613-9758-30076FDC9C83 Q26775578-8F195642-67B6-46D4-864B-F6DACAC7EB37 Q26775591-649A40AB-9682-4FB7-8E78-96BFEE4B3FDE Q26775769-ED03047F-24B7-4965-A0FE-2BDC0D7F4660 Q26777557-2217A4D3-F343-410B-92F8-F321CB5FEA1D Q26778296-F5307A79-D325-45E9-BA76-45C18B439A85 Q26778765-A38F0B91-B62E-4764-AF53-FBEBB5323CEA Q26778790-D561BB12-F02A-43E2-8623-BDA9B90DB659 Q26795598-CEDDE596-9BD4-4268-8AD8-200A7A77F44F Q26796311-7F7C474E-1DCF-48E5-9DE7-FED6A8EEE194 Q26797282-D8E8C33C-56A3-4689-811A-F1E5628BA7A1 Q26797478-147DCBB1-8729-449B-8469-E205B202555F Q26798330-859DABBB-AF38-4FFB-8A21-0640B46BB07F Q26823789-13EDFE39-D8E8-4005-ADCD-406D08AFD497

P2860

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

http://www.wikidata.org/entity/Q29620051

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase I study of single-agent ...... cs, and immunologic correlates

@ast

Phase I study of single-agent ...... cs, and immunologic correlates

@en

type

label

Phase I study of single-agent ...... cs, and immunologic correlates

@ast

Phase I study of single-agent ...... cs, and immunologic correlates

@en

prefLabel

Phase I study of single-agent ...... cs, and immunologic correlates

@ast

Phase I study of single-agent ...... cs, and immunologic correlates

@en

P1433

Q29620051-6F12E6B4-66DC-4D03-A10F-0A9BA87EB6FD

P1476

Q29620051-1D7F41AE-5ED5-4BBD-8F39-AD8121A0AA8E

P2093

Q29620051-09B9EDD4-1CEA-4DE3-8B61-BB016DE7141C

Q29620051-193D0F1C-C349-4B84-BBE8-2B8E45A1CE80

Q29620051-3B059946-F3AA-4D04-B97A-A981EF1E89D3

Q29620051-535D0742-EC55-48EE-99ED-FDD836655CE8

Q29620051-75812B9D-0916-4769-8B9D-1FA5F44A5F43

Q29620051-789AF95C-A996-45DC-80D1-7FDABBDFB56E

Q29620051-79079532-0827-4980-8C68-A10EBB5CA03F

Q29620051-913EB9C1-758E-42EC-88D1-8F68922643AB

Q29620051-A504233F-A2C6-4CFF-ADEA-57C7C233A483

Q29620051-A6763C93-CDBD-45BF-A3B6-85FC4350FEBF

P2860

Q29620051-005CA854-FA53-495F-98B9-94DB05CB0592

Q29620051-0E7AE7A5-A9EF-4020-9518-E57BD7906B98

Q29620051-1D8B140F-FE50-4D3A-9AF6-367641EFE05D

Q29620051-2032C508-D2BB-410D-BCBB-612D4A75713D

Q29620051-2955B525-38F5-49C3-B1CF-6C41FF797AF1

Q29620051-32758F39-12D7-4E28-8AA9-297741D945F4

Q29620051-37484DE8-6C89-4ED5-9619-36FEF22B04DD

Q29620051-4377CAE5-4713-4743-BA22-30499D34032E

Q29620051-7E0EB7D0-4A69-4D9F-A4E4-140D6F47539B

Q29620051-885641D6-ACA6-44D9-900B-1E4B583A0535

P304

Q29620051-0BDD2F3C-DB64-40EF-8ED0-449B58693C63

P31

Q29620051-120B280F-827B-4997-A18F-C88022EC9D34

P3181

Q29620051-BB42FF4A-A58F-48E9-B856-FA002D2C9EF9

P356

Q29620051-2A98357D-E189-42CF-BDD3-804BDF2DFAD3

P407

Q29620051-00A908FB-D423-4EAE-9EF6-7BB868E74E8F

P433

Q29620051-104A5365-5AF4-403F-AFC0-FFE23C75927C

P478

Q29620051-FB1B6693-1D65-4AB0-9FE9-B89A23F1FAE4

P577

Q29620051-579195D0-89C1-474A-82F1-DA3AB0827E3F

P698

Q29620051-E027D6F0-BB47-4007-94E5-12C7283582F0

P921

Q29620051-7861B0A1-8F19-4AF6-B7B8-F11305AE46D4

P932

Q29620051-EBAB61F4-B771-4E12-9507-8701C77B5C10

P3181

P356

JCO.2009.26.7609

P1433

Journal of Clinical Oncology

P1476

Phase I study of single-agent ...... cs, and immunologic correlates

@en

P2093

Anders R

http://www.w3.org/2001/XMLSchema#string

Brahmer JR

http://www.w3.org/2001/XMLSchema#string

Chen L

http://www.w3.org/2001/XMLSchema#string

Drake CG

http://www.w3.org/2001/XMLSchema#string

Gilson MM

http://www.w3.org/2001/XMLSchema#string

Korman AJ

http://www.w3.org/2001/XMLSchema#string

Lowy I

http://www.w3.org/2001/XMLSchema#string

McMiller TL

http://www.w3.org/2001/XMLSchema#string

Pardoll DM

http://www.w3.org/2001/XMLSchema#string

Picus J

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells

P304

3167-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

886312

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2009.26.7609

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20516446

http://www.w3.org/2001/XMLSchema#string

P921

pharmacodynamics

P932

4834717

http://www.w3.org/2001/XMLSchema#string